natgillin/translations-raw huggingface dataset:
For more information about treatment with Ketek, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Ketek preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Prescribers should consider official guidance on the use of antibacterial agents and local levels of resistance to antibiotics. 
Osebe, ki zdravilo predpišejo, morajo upoštevati uradne smernice o uporabi protibakterijskih sredstev in lokalne ravni odpornosti proti antibiotikom.
Ketek was as effective as the comparator antibiotics. 
Zdravilo Ketek je bilo enako učinkovito kot primerjalni antibiotiki.
The main measure of effectiveness was the proportion of patients who were cured at the end of treatment as determined by a reduction in symptoms, or who had ‘satisfactory' reductions in the amount of bacteria detected in samples taken 
Glavno merilo učinkovitosti je bil delež bolnikov, ki so ob koncu zdravljenja ozdraveli, kakor je pokazalo zmanjšanje simptomov, oziroma delež bolnikov z zadovoljivim zmanjšanjem količine bakterij, odkritih v vzorcih, vzetih iz grla.
The recommended dose of Ketek is 800 mg (two tablets) once a day. 
Priporočeni odmerek zdravila Ketek je 800 mg (dve tableti) enkrat na dan. Tablete je treba pogoltniti cele z vodo.
The most common side effect with Ketek (seen in more than 1 patient in 10) is diarrhoea. 
Najpogostejši neželeni učinek zdravila Ketek (opažen pri več kot 1 bolniku od 10) je driska.
Taking Ketek at bedtime may reduce the potential impact of side effects such as visual disturbances and loss of consciousness. 
Jemanje zdravila Ketek pred spanjem lahko zmanjša morebitni vpliv neželenih učinkov, kot sta motnja vida ali izguba zavesti.
Telithromycin works by blocking the bacteria's ribosomes (the parts of the cells where proteins are produced), inhibiting the growth of the bacteria. 
Telitromicin deluje tako, da zavre ribosome bakterij (dele celice, kjer se tvorijo beljakovine) in s tem preprečuje rast bakterij.
The CHMP concluded that Ketek's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ketek večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
All but two of the studies compared Ketek with other antibiotics. 
V vseh študijah razen dveh so zdravilo Ketek primerjali z učinki drugih antibiotikov.
Ketek is a medicine that contains the active substance telithromycin. 
Ketek je zdravilo, ki vsebuje zdravilno učinkovino telitromicin.
However, the Committee noted that Ketek is associated with a greater risk of certain side effects than other antibiotics. 
Vendar je opomnil, da je zdravilo Ketek povezano z večjim tveganjem pojava določenih neželenih učinkov kot drugi antibiotiki.
• acute sinusitis (short-lived infection of the sinuses, air-filled passageways in the bones around the 
• akutnim sinuzitisom (kratkotrajno okužbo sinusov, z zrakom napolnjenih prehodov v kosteh okrog
Ketek must not be taken by patients with a history or a family history of ‘long QT syndrome' or with ‘acquired QT interval prolongation' (disruption of the heartbeat). 
Zdravila Ketek ne smejo jemati bolniki z anamnezo ali družinsko anamnezo „sindroma podaljšanega intervala QT“ ali s „pridobljenim podaljšanjem intervala QT“ (motnjo srčnega ritma).
For pneumonia and chronic bronchitis, Ketek was as effective as amoxicillin, clarithromycin, trovafloxacin, amoxicillin/clavulanic acid and cefuroxime axetil, with between 82 and 95% of the patients having no symptoms at the end of treatment. 
Pri pljučnici in kroničnem bronhitisu je bilo zdravilo Ketek enako učinkovito kot amoksicilin, klaritromicin, trovafloksacin, amoksicilin/klavulanska kislina in cefuroksim aksetil, pri čemer ob koncu zdravljenja med 82 in 95 % bolnikov ni imelo nobenih simptomov.
A lower dose may be needed in patients who have severe kidney problems. 
Pri bolnikih s hudimi ledvičnimi težavami bo morda potreben manjši odmerek.
Ketek must not be used in people who are hypersensitive (allergic) to telithromycin, any macrolides, or any of the other ingredients. 
Zdravila Ketek ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) telitromicin, kateri koli makrolid ali katero koli drugo sestavino zdravila.
How is Ketek used? 
Kako se zdravilo Ketek uporablja?
Four studies looked at its effects in mild to moderate community-acquired pneumonia, two looked at acute sinusitis, two looked at acute exacerbations of chronic bronchitis and two looked at tonsillitis or pharyngitis. 
V štirih študijah so proučevali učinke zdravila na blago do zmerno pljučnico, dobljeno v domačem okolju, v dveh študijah so opazovali učinke na akutni sinuzitis, v dveh učinke na akutno poslabšanje kroničnega bronhitisa, v dveh pa so proučevali učinke na tonzilitis ali faringitis.
It is also used to treat adults with the following infections when they are caused by bacteria that are or could be resistant (insensitive) to beta-lactams or macrolides (types of antibiotic): 
Uporablja se tudi za zdravljenje odraslih z naslednjimi okužbami, ki so jih povzročile bakterije in ki so ali bi lahko bile odporne proti betalaktamom ali makrolidom (vrsti antibiotikov) ali neobčutljive nanje:
The full list of bacteria against which Ketek is active can be found in the summary of product characteristics (also 
Celoten seznam bakterij, proti katerim je zdravilo Ketek učinkovito, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
Ketek is also used to treat patients aged 12 years or over who have tonsillitis or pharyngitis (infections of the tonsils or throat) caused by the bacterium Streptococcus pyogenes. 
Zdravilo Ketek se uporablja tudi za zdravljenje bolnikov, starejših od 12 let, s tonzilitisom ali faringitisom (vnetjem mandljev ali grla), ki jo povzroča bakterija Streptococcus pyogenes.
• acute exacerbation (flare-up) of chronic bronchitis (long-lasting inflammation of the airways in the 
• akutnim poslabšanjem (ponovnim izbruhom) kroničnega bronhitisa (dolgotrajnega vnetja dihalnih
It must not be used in patients with myasthenia gravis (a disease of the nerves causing muscle weakness), or who have had hepatitis (inflammation of the liver) or jaundice when they have taken telithromycin in the past. 
Zdravila ne smejo uporabljati bolniki z miastenijo gravis (boleznijo živcev, pri kateri postajajo mišice šibke), bolniki, ki so imeli hepatitis (vnetje jeter) ali zlatenico, ko so v preteklosti jemali telitromicin.
The active substance in Ketek, telithromycin, is an antibiotic belonging to the class ‘ketolides'. 
Zdravilna učinkovina zdravila Ketek, telitromicin, je antibiotik iz skupine „ketolidov“.
Therefore, the Committee decided that its use should be reserved to the treatment of communityacquired pneumonia, to the treatment of bronchitis and sinusitis when caused by bacteria that are resistant to beta-lactam or macrolide antibiotics, and to tonsillitis/pharyngitis when these antibiotics 
Odbor je zato zaključil, da je treba uporabo zdravila omejiti na zdravljenje pljučnice, pridobljene v domačem okolju, zdravljenje bronhitisa in sinuzitisa, povzročenih z bakterijami, ki so odporne na betalaktamske ali makrolidne antibiotike ter na zdravljenje tonzilitisa/faringitisa, če teh antibiotikov ni mogoče uporabiti.
In patients with acute sinusitis, five- and 10-day courses of Ketek led to similar cure rates, which were similar to that seen with amoxicillin/clavulanic acid. 
Pri bolnikih z akutnim sinuzitisom so bile stopnje ozdravitve po 5- in 10-dnevnem zdravljenju z zdravilom Ketek podobne tistim, opaženim ob uporabi amoksicilina/klavulanske kisline.
For more information, see 
Za več informacij glejte navodilo za uporabo.
For the full list of all side effects reported with Ketek, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ketek, glejte navodilo za uporabo.
For tonsillitis or pharyngitis, between 84 and 92% of the patients taking Ketek, penicillin or clarithromycin had a satisfactory reduction in bacterial levels 
Pri tonzilitisu ali faringitisu je bilo znižanje količin bakterij v vzorcih, ki so jih odvzeli iz grla, zadovoljivo pri 84-92 % bolnikov, ki so jemali zdravilo Ketek, penicilin ali
It is available as tablets 
Na voljo je v obliki tablet (400 mg).
Ketek is used to treat adults with mild or moderate community-acquired pneumonia (an infection of the lungs that is caught outside of hospital). 
Zdravilo Ketek se uporablja za zdravljenje odraslih z blago ali zmerno pljučnico, dobljeno v domačem
The application was withdrawn at ‘day 120'. 
Vlogo so umaknili na „120.
This means that the CHMP had evaluated the initial documentation provided by the company and formulated a list of questions. 
To pomeni, da je CHMP dotlej ocenil začetno dokumentacijo, ki jo je predložila družba, in oblikoval sezname vprašanj.
The CHMP also noted that the clinical relevance of the study results was unclear. 
CHMP je prav tako navedel, da klinična pomembnost rezultatov študije ni jasna.
The main measures of effectiveness were based on the sensitivity of the scans (how well they detected abnormalities in the ducts) and their specificity (how well normal ducts were identified as normal). 
Glavna merila za učinkovitost so temeljila na občutljivosti slikanja (kako dobro je slikanje zaznalo nepravilnosti v duktusih) in njegovi specifičnosti (kako dobro so bili normalni duktusi prepoznani kot normalni).
Withdrawal of the marketing authorisation application for SecreFlo (secretin human) EMA/602611/2012 
Umik vloge za pridobitev dovoljenja za promet z zdravilom SecreFlo (humani sekretin) EMA/602611/2012
SecreFlo is a medicine that contains the active substance secretin human. 
SecreFlo je zdravilo, ki vsebuje zdravilno učinkovino humani sekretin.
The Committee was concerned that there may not have been adequate safeguards to ensure that the final readings of the scans were not biased. 
Odbor je menil, da morda ni bilo zadostnih zaščitnih ukrepov, s katerimi bi zagotovili, da so končne interpretacije slik nepristranske.
On 15 August 2012, Repligen Europe Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for SecreFlo, intended for use in the detection of duct abnormalities in the pancreas. 
Družba Repligen Europe Limited je dne 15. avgusta 2012 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom SecreFlo, namenjenim za uporabo pri odkrivanju nepravilnosti v duktusih v trebušni slinavki.
In its letter notifying the Agency of the withdrawal of application, the company stated that the withdrawal was based on the fact that the concerns raised by the CHMP could not be addressed in the available timeframe. 
Družba je v svojem dopisu, v katerem agencijo obvešča o umiku svoje vloge, navedla, da umik temelji na dejstvu, da pomislekov, ki jih je izpostavil CHMP, ni bilo mogoče obravnavati v razpoložljivem časovnem okviru.
Images from the scans were read by expert radiologists without prior knowledge of the patients' condition and the results were compared with what was already known from other tests. 
Slike so interpretirali specialisti radiologi, ki niso poznali bolnikovega stanja, rezultate pa so primerjali s podatki, ki so bili znani iz predhodnih preiskav.
Withdrawal of the marketing authorisation application for SecreFlo (secretin human) 
Umik vloge za pridobitev dovoljenja za promet z zdravilom SecreFlo (humani sekretin)
Another concern was the fact that patients in the study (patients with a history of acute pancreatitis) were not representative of patients for whom the medicine was intended (patients with known or suspected pancreatitis). 
Drugi pomislek odbora je bil, da bolniki v študiji (bolniki z akutnim pankreatitisom v anamnezi) niso bili reprezentativni za bolnike, ki jim je zdravilo namenjeno (bolnikom s potrjenim pankreatitisom ali sumom nanj).
The company presented data from one main study, which involved 270 patients with a history of acute pancreatitis who had MRI scans with or without previous SecreFlo injections. 
Družba je predstavila podatke iz ene glavne študije, ki je vključevala 270 bolnikov z akutnim pankreatitisom v anamnezi, pri katerih so opravili slikanje z magnetno resonanco s predhodnim injiciranjem zdravila SecreFlo ali brez njega.
Being able to see abnormalities in the pancreatic ducts is important for making decisions on how to treat these patients. 
Vizualizacija nepravilnosti v duktusih trebušne slinavke je pomembna pri odločanju o izbiri zdravljenja pri teh bolnikih.
What is SecreFlo? 
Kaj je zdravilo SecreFlo?
The company informed the CHMP that there were no ongoing clinical trials with SecreFlo at the time of the withdrawal. 
Družba je CHMP obvestila, da v času umika niso potekala nobena klinična preskušanja z zdravilom SecreFlo.
At the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that SecreFlo could not have been approved. 
V času umika je CHMP izrazil določene zadržke in je začasno menil, da zdravila SecreFlo ni mogoče odobriti.
What was SecreFlo expected to be used for? 
Za kaj naj bi se zdravilo SecreFlo uporabljalo?
The active substance in SecreFlo is a copy of human secretin, a natural hormone that stimulates the pancreas to secrete fluids into the small intestine. 
Zdravilna učinkovina v zdravilu SecreFlo je kopija humanega sekretina, naravnega hormona, ki spodbuja trebušno slinavko k izločanju tekočine v tanko črevo.
SecreFlo was expected to be used in patients undergoing magnetic resonance imaging (MRI, a type of scan where images of the internal organs are taken) to obtain a clearer image of their pancreas. 
Zdravilo SecreFlo naj bi se uporabljalo pri bolnikih, pri katerih opravijo slikanje z magnetno resonanco (MRI, vrsto slikanja, pri katerem se posnamejo slike notranjih organov), da se pridobi jasnejša slika trebušne slinavke.
How is SecreFlo expected to work? 
Kako naj bi zdravilo SecreFlo delovalo?
SecreFlo was to be injected into a patient's vein just before undergoing a MRI scan. 
Zdravilo SecreFlo je treba injicirati v bolnikovo veno tik pred slikanjem z magnetno resonanco.
It was to be used in patients with known or suspected pancreatitis (inflammation of the pancreas) so that abnormalities in the small ducts within the pancreas can be seen more clearly. 
Uporabljalo naj bi se pri bolnikih s potrjenim pankreatitisom (vnetjem trebušne slinavke) ali sumom nanj, da bi lahko zdravniki jasneje videli nepravilnosti v majhnih duktusih v trebušni slinavki.
The medicine's use in visualising the pancreatic ducts is based on its action of stimulating fluid secretion, which causes the ducts in the pancreas to widen significantly and therefore appear more clearly in a scan. 
Uporaba tega zdravila za vizualizacijo duktusov trebušne slinavke temelji na tem, da zdravilo spodbuja izločanje tekočine, kar povzroči znatno razširitev duktusov v trebušni slinavki, zato so ti pri slikanju bolje vidni.
The scans had had to be read a second time after initial readings were deemed unreliable. 
Ker je odbor menil, da so prvotne interpretacije nezanesljive, je bilo treba slike ponovno interpretirati.
-- 1 Inactivated West Nile virus, strain VM-2: RP* 1.0-2.2/ml. 
-- 1 Inaktiviran virus West Nile, sev VM-2
* Relative potency by in vitro method, compared to a reference vaccine that was shown efficacious in horses. 
RP* 1,0-2,2 *Relativna učinkovitost (Relative Potency) pri in vitro metodi v primerjavi z referenčnim cepivom, ki je bilo učinkovito pri konjih.
Unopened: 3 years 
Neodprto: 3 leta
Your doctor will know about this. 
Zdravnik je s tem seznanjen.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 28 July 2015 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 28. julij 2015
This leaflet was last revised in <date of Commission Decision> 
Navodilo je bilo nazadnje revidirano dne <datum odločbe Komisije>
Therefore, no interaction is expected. 
Medsebojnega delovanja zato ni pričakovati.
E-mail: regulatory@omeros.ie 
E-pošta: regulatory@omeros.ie
The following instructions must be adhered to: 
Upoštevati morate naslednja navodila:
From a microbiological point of view, the medicinal product should be used immediately. 
Z mikrobiološkega stališča je treba zdravilo porabiti takoj.
The elderly population has been studied in clinical studies. 
Starejšo populacijo so proučevali v kliničnih študijah.
Prevention of miosis was confirmed in a categorical analysis. 
Preprečevanje mioze je potrdila kategorična analiza.
Nineteen percent of cataracts were LOCS II Nuclear Grade 2 or 3. 
Devetnajst odstotkov katarakt je bilo uvrščenih med nuklearne katarakte stopnje 2 ali 3 po LOCS II.
A significant reduction in ocular pain during the initial 10-12 hours postoperatively was also demonstrated. 
Študiji sta pokazali tudi pomembno zmanjšanje bolečine v očesu v prvih 10-12 urah po operaciji.
The risk of blood pressure elevations may be increased in patients requiring prolonged surgery. 
Tveganje za zvišanje krvnega tlaka se lahko poveča pri bolnikih, pri katerih je potreben daljši kirurški poseg.
If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vam dajo to zdravilo.
Component of a multipack, cannot be sold separately. 
Del pakiranja z več vialami, ne sme se prodajati posebej.
The frequency of adverse reactions is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Patients were randomised to either Omidria or placebo (1:1). 
Bolnike so randomizirali tako, da so prejemali bodisi zdravilo Omidria ali placebo (1 : 1).
Do not use this medicine after the expiry date which is stated on the carton after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake „EXP“.
The population in the trials was 26 to 90 years of age (59% female, 41% male; 80% white, 12% black and 8% other race). 
Starost populacije v preskušanjih je bila od 26 do 90 let (59 % žensk, 41 % moških; 80 % belcev, 12 % črncev in 8 % oseb druge rase).
The safety and efficacy of Omidria in children below the age of 18 years has not been established. 
Varnost in učinkovitost zdravila Omidria pri otrocih, mlajših od 18 let, nista bili dokazani.
Omidria should not be used in children and adolescents below the age of 18 as it has not been studied in these groups. 
Zdravilo Omidria se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let, saj pri teh skupinah ni bilo raziskano.
After dilution, chemical and physical in-use stability has been demonstrated for 6 hours at 25 ˚C. 
Dokazano je bilo, da je po redčenju raztopina kemično in fizikalno stabilna 6 ur pri temperaturi 25 ˚C.
Pharmacotherapeutic group: {Not yet assigned}, ATC code: {Not yet assigned} 
Farmakoterapevtska skupina: {še ni bila dodeljena}, oznaka ATC: {še ni bila dodeljena}
If you are able to become pregnant, you should be using suitable contraception before you are given Omidria. 
Če lahko zanosite, morate uporabljati ustrezno kontracepcijo, preden vam dajo zdravilo Omidria.
Side effects affecting the eye: 
Neželeni učinki, ki prizadenejo oko:
4.7 Effects on ability to drive and use machines Omidria can have a major influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Zdravilo Omidria ima pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
Anticipated systemic exposure is minimal and transient, however, caution should be used in treating patients with poorly controlled hypertension. 
Pričakovati je mogoče zelo majhno in prehodno sistemsko izpostavljenost, kljub temu pa je potrebna previdnost pri zdravljenju bolnikov s slabo nadzorovano hipertenzijo.
Therefore, use Omidria with caution in individuals who have previously exhibited sensitivities to these active substances. 
Zdravilo Omidria zato previdno uporabljajte pri osebah, ki so že kdaj bile občutljive za omenjene zdravilne učinkovine.
This medicine can have a major influence on the ability to drive and use machines. 
Zdravilo ima pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
Each of these same findings was reported at a similar frequency in patients receiving placebo. 
O vseh teh neželenih učinkih so podobno pogosto poročali tudi pri bolnikih, ki so prejeli placebo.
If any of the above applies to you, please inform your doctor. 
Če karkoli od navedenega velja za vas, o tem obvestite zdravnika.
For any information about this medicine, please contact the Marketing Authorisation Holder: 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
The European Medicines Agency has deferred the obligation to submit the results of studies with Omidria in one or more subsets of the paediatric population in lens therapeutic procedures (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Omidria za eno ali več podskupin pediatrične populacije pri terapevtskih posegih na očesni leči (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
The safety profile of Omidria is based on data from 459 adult patients collected during clinical development obtained in randomised controlled trials. 
Varnostni profil zdravila Omidria temelji na podatkih o 459 odraslih bolnikih, pridobljenih v randomiziranih kliničnih preskušanjih v okviru kliničnega razvoja.
Omidria must not be used: 
Zdravilo Omidria se ne sme uporabljati:
- One of the active substances in Omidria can react with several types of anaesthetics. 
- Ena od zdravilnih učinkovin v zdravilu Omidria lahko reagira z več vrstami anestetikov.
These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases. 
Ti neželeni učinki, med katerimi so bili tudi smrtni, so se običajno pojavili pri bolnikih, ki so že prej imeli srčno-žilne bolezni.
The maximum ketorolac concentration seen was 4.2 ng/mL. 
Največja opažena koncentracija ketorolaka je bila 4,2 ng/ml.
Ketorolac plasma concentrations were detected in 11 of 14 patients. 
Plazemske koncentracije ketorolaka so zaznali pri 11 od 14 bolnikov.
Fifty-three percent of patients had brown irides, 28% had blue irides, and 19% had irides of other colours. 
Triinpetdeset odstotkov bolnikov je imelo rjavo šarenico, 28 % modro šarenico in 19 % šarenico druge barve.
See section 4.8 for further details regarding possible visual disturbances. 
Za dodatne informacije o možnih motnjah vida glejte poglavje 4.8.
These concentrations are over 10-fold higher than the concentration of each agent administered clinically in patients receiving Omidria. 
Te koncentracije so več kot 10-krat večje od koncentracije posamezne učinkovine, ki se v klinični praksi uporablja pri bolnikih, ki prejmejo zdravilo Omidria.
Detectable phenylephrine plasma concentrations were observed in only one of 14 patients. 
Zaznavne koncentracije fenilefrina v plazmi so opazili samo pri enem od 14 bolnikov.
The used vial and any unused irrigation solution must be discarded after single use in accordance with local requirements. 
Uporabljeno vialo in morebitno neporabljeno raztopino za izpiranje po enkratni uporabi zavrzite v skladu z lokalnimi predpisi.